HLA-G and renal cell carcinoma: Moreover, considering the fact that there is known aberrant activation of HLA-G and HLA-E expression by interferons, then identification of HLA-G and HLA-E status could have an impact on the design of T and NK cell-based immunotherapies in this disease and contribute to better selection of RCC patients who could possibly benefit from more tailored neoadjuvant biological/immunological therapy.